Reglan and Tardive Dyskinesia: Recognizing Symptoms in Illinois

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Exposure Concerns

If you or a loved one has taken Reglan and noticed involuntary muscle movements, you may be witnessing tardive dyskinesia. Recognizing these symptoms early is crucial for management. The medical community has long studied medication-induced movement disorders, and this page explains the specific signs to watch for and how diagnosis is made in Illinois.

Reglan, Tardive Dyskinesia, and the Importance of Timely Legal Action

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux disease (GERD) and diabetic gastroparesis. The FDA-approved labeling explicitly states that Reglan is indicated for treatment of GERD for 4 to 12 weeks and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also notes that Reglan has not been shown to be safe and effective for GERD beyond 12 weeks and is not recommended for pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is a serious movement disorder characterized by potentially irreversible and disfiguring involuntary movements of the face, tongue, trunk, and extremities. The condition is clinically diagnosed based on the presence of these abnormal movements, which can include lip smacking, grimacing, tongue protrusion, and rapid eye blinking. The FDA boxed warning for Reglan states that metoclopramide can cause TD, and the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning further notes that Reglan is contraindicated in patients with a history of TD and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism of Action and Risk Factors for Tardive Dyskinesia

The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the basal ganglia is believed to lead to upregulation of these receptors and subsequent supersensitivity, which manifests as involuntary movements. The FDA warnings and precautions section explains that metoclopramide can cause TD and may also suppress or partially suppress signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect is a critical concern because it can allow the condition to progress unnoticed until movements become severe. The adequacy of warnings regarding Reglan and TD is a central issue in litigation. The FDA boxed warning, which is the strongest safety warning, clearly states that metoclopramide can cause TD and that the risk increases with longer treatment and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite this, many patients were prescribed Reglan for extended periods, sometimes years, exceeding the recommended 12-week maximum for GERD and the 12-week limit for diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling advises that if longer-term use is unavoidable, patients should be routinely monitored for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, in practice, monitoring was often inadequate, and many patients developed TD without being warned of the risk or being monitored appropriately.

Statute of Limitations for Reglan Claims in Illinois

Settlement-related considerations for affected patients in Illinois involve the statute of limitations, which is the time limit for filing a lawsuit. In Illinois, the statute of limitations for personal injury claims, including those related to TD from Reglan, is generally two years from the date the injury was discovered or should have been discovered. This discovery rule is critical because TD can develop insidiously over months or years of Reglan use. The timeline between exposure and documented harm is variable; some patients develop symptoms within weeks, while others may not show signs until after years of use. The FDA boxed warning emphasizes that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), meaning that longer exposure correlates with higher risk. For patients who took Reglan for extended periods, the onset of TD may occur after discontinuation, further complicating the discovery timeline. Patients considering legal action must be aware that the statute of limitations begins when they knew or reasonably should have known that their TD was caused by Reglan. This may require medical confirmation of the diagnosis and a link to the medication. Given that TD can be misdiagnosed or attributed to other causes, the clock may not start until a physician explicitly identifies the connection. In Illinois, courts have applied the discovery rule in pharmaceutical cases, but the burden is on the plaintiff to show that the injury was not discoverable earlier.

Legal Considerations and Evidence for Reglan TD Claims

For settlement purposes, the strength of a claim depends on evidence of prolonged Reglan use beyond recommended durations, lack of adequate warnings provided to the patient, and documented development of TD. The FDA labeling explicitly states that Reglan should be used for the shortest duration and that patients should be periodically reassessed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to follow these guidelines may support a claim of inadequate warning or negligence. Additionally, the contraindication for patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397) means that prescribing Reglan to such patients would be a clear deviation from standard care. In summary, the medical and legal landscape for Reglan-related TD in Illinois requires careful attention to the statute of limitations, which is typically two years from discovery. The FDA warnings provide strong evidence of known risks, and the duration of use is a key factor in both medical risk and legal liability. Patients who developed TD after prolonged Reglan use, especially beyond 12 weeks, should seek legal counsel promptly to assess their claims within the applicable time frame.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Illinois?

In Illinois, the statute of limitations for personal injury claims, including those related to tardive dyskinesia from Reglan, is generally two years from the date the injury was discovered or should have been discovered. This discovery rule is critical because TD can develop insidiously over months or years of Reglan use. Patients should seek legal counsel promptly to assess their claims within this time frame.

What evidence is needed to support a Reglan tardive dyskinesia claim?

Key evidence includes documentation of prolonged Reglan use beyond the recommended 12-week duration, lack of adequate warnings provided to the patient, and a confirmed diagnosis of tardive dyskinesia linked to Reglan. The FDA boxed warning and labeling provide strong evidence of known risks, and failure to follow prescribing guidelines may support a claim of negligence.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Reglan Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.